In recent years, acetylcholinesterase inhibitors have been approved for the treatment of Alzheimer's disease. This has been mainly on the strength of many randomised placebocontrolled trials showing a statistically significant improvement in cognitive, functional and behavioural scores mainly at 12 and 24 weeks. 1, 2, 3 The questions now are whether this statistical difference translates into a clinically meaningful difference and whether treatment is cost-effective. The AD2000 trial 4 sheds light on this question.
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This placebo-controlled trial of donepezil was not sponsored by a drug company. The trial has many strengths as it:
■ is the only trial to look at end points beyond one year ■ focuses primarily on clinical end points such as time to institutionalisation or progression to disability ■ includes measures of caregiver burden (as a secondary outcome)
■ enrolled a broader spectrum of patients than those typically included in trials sponsored by drug companies.
The drawbacks of the trial were that recruitment was slower and smaller than planned (566 versus 3000 patients). It had a complex design (multiple treatment phases and washout periods) and a large withdrawal rate. This makes a true intention-to-treat analysis difficult, however, the overall effect of these factors is to bias away from the null, that is to overstate the effect size. With this caveat in mind, the results show: So what can we say in summary? This trial once again highlights the importance of independent trials that enrol a representative patient population. Previous work shows that industry-sponsored studies tend to have more favourable results than non-industry studies. 6, 7 This may be a consequence of inclusion and exclusion criteria that are very tightly defined and implemented. After the initial wave of favourable, mainly company-sponsored, results using cognitive and behavioural scales, AD2000 suggests that these changes in scores do not translate into clinically important or cost-effective changes. It is also evident that most of the relative improvement in scores occurs in the first six months.
Prolonged use does not continue to improve scores, although it is unclear whether this is needed to maintain the benefit or if stopping will accelerate the patient's decline.
Note
While this article was under review, another study looking at the effect of donepezil and vitamin E on cognitive impairment 
